Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : U.S. FDA advisers to review Merck's oral COVID-19 drug next month

10/14/2021 | 12:57pm EST

Oct 14 (Reuters) - A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co's experimental COVID-19 antiviral drug, the agency said on Thursday.

The U.S. Food and Drug Administration's (FDA) panel will meet on Nov. 30 to discuss safety and effectiveness of the drug, molnupiravir, for the treatment of mild-to-moderate COVID-19 in adults who have tested positive and are at high risk for progression to severe illness. (https://refini.tv/3p1PETq)

The FDA typically follows the advice of its experts but is not bound to do so.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir, which it is developing with partner Ridgeback Biotherapeutics. The drug would become the first oral antiviral medication for COVID-19, if cleared by the agency.

Pfizer Inc and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for the disease.

Merck's treatment cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month.

The company has a contract with the U.S. government to supply 1.7 million courses at a price of $700 per course. The drugmaker also recently signed deals with Malaysia and Singapore for supply of the drug.

Bloomberg News first reported on a U.S. FDA advisory committee review of the drug. (Reporting by Amruta Khandekar; Editing by Maju Samuel and Shailesh Kuber)


ę Reuters 2021
All news about ROCHE HOLDING AG
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Shareholders OK $21 Billion Repurchase Deal With Novartis
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Extraordinary General Meeting 2021
AQ
11/24ROCHE HOLDINGS AG : UBS sticks Neutral
MD
11/24ROCHE HOLDINGS AG : Buy rating from Deutsche Bank
MD
11/23Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfoli..
BU
11/23Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, c..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 134 M 67 309 M 67 309 M
Net income 2021 15 285 M 16 558 M 16 558 M
Net cash 2021 4 385 M 4 750 M 4 750 M
P/E ratio 2021 19,5x
Yield 2021 2,60%
Capitalization 310 B 336 B 336 B
EV / Sales 2021 4,92x
EV / Sales 2022 4,81x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 358,60 CHF
Average target price 388,44 CHF
Spread / Average Target 8,32%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.05%336 162
JOHNSON & JOHNSON1.82%419 109
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049
ABBVIE INC.8.74%205 976